# S-Refit

> S-Refit is a VC fund in Regensburg backing Biotechnology, Medical and Health Care. See 2 investments, round sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Regensburg, Germany
- Total investments: 2
- Last investment: May 2014
- Lead investor: 0%
- Last updated: Aug 2026
- Website: http://www.s-refit.de

S-Refit is a German venture capital firm that invests in biotechnology, mechanical engineering, and software companies.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 100% |
| Medical | 1 | 50% |
| Health Care | 1 | 50% |
| Therapeutics | 1 | 50% |
| Health Diagnostics | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Funding Round | 1 | 50% |
| Private Equity | 1 | 50% |

## Investments

| Company | Description | Round size | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Lophius Biosciences | Lophius Biosciences is a young biotechnology company developing innovative products for the diagnosis of acute infectious and autoimmune diseases. The company is also offering custom-made services in the area of cell based bioactivity and quality tests for pharmaceutical agents. The core competencies of Lophius Biosciences are in the area ofImmunology and T-cell diagnostics.Lophius Biosciences is a privately-held German biotechnology company focusing on the development and marketing of innovative immune diagnostic systems to improve therapy control and personalized treatment of patients in the area of transplantation, infectious and autoimmune diseases.The company’s developments are based on its expertise in cell-mediated immunity as well as on its proprietary T-activation® and Reverse T Cell Technology platforms. Whereas the T-activation® technology platform allows an efficient stimulation of a broad spectrum of clinically-relevant immune effector cells to accurately measure the cell-mediated immunity, the Reverse T Cell Technology platform can distinguish between active and memory T cells to develop innovative diagnostics. | $2.2M |  | May 08, 2014 | http://www.lophius.com/ |
| Isarna Therapeutics | Isarna Therapeutics has an unmatched commitment to developing selective TGF-β inhibitors to effectively treat ophthalmic diseases. They are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes. | $18M | Private Equity | Dec 01, 2005 | http://www.isarna-therapeutics.com |

2 of 2 investments shown.

## Co-investors
- [Global Asset Capital](https://shizune.co/investors/profile/global-asset-capital) — VC Fund, 1 deal together
- [Global Chance Fund](https://shizune.co/investors/profile/global-chance-fund) — VC Fund, 1 deal together
- [Heidelberg Innovation](https://shizune.co/investors/profile/heidelberg-innovation) — VC Fund, 1 deal together
- [MIG Capital](https://shizune.co/investors/profile/mig-ag) — VC Fund, 1 deal together
- [VRD GmbH](https://shizune.co/investors/profile/vrd-gmbh-2) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund

### Similar country
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund
- [HV Capital](https://shizune.co/investors/profile/holtzbrinck-ventures) — VC Fund
- [IBB Ventures](https://shizune.co/investors/profile/ibb) — VC Fund

## Featured in investor lists
- [Biotech VC Funds in Germany](https://shizune.co/investors/biotech-vc-funds-germany)
- [Biotech Investors in Germany](https://shizune.co/investors/biotech-investors-germany)

## FAQ

### What does S-Refit invest in?

S-Refit invests primarily in Biotechnology, Medical and Health Care startups, most often at Funding Round and Private Equity stage. Most of the 2 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did S-Refit last invest?

The most recent investment recorded for S-Refit closed in May 2014. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co